{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:08Z","timestamp":1793382908104,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13011-019-0195-4","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T10:04:16Z","timestamp":1550484256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Higher doses of naloxone are needed in the synthetic opioid era"],"prefix":"10.1186","volume":"14","author":[{"given":"Ronald B.","family":"Moss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"195_CR1","unstructured":"https:\/\/www.surgeongeneral.gov\/priorities\/opioid-overdose-prevention\/naloxone-advisory.html"},{"key":"195_CR2","unstructured":"https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html"},{"key":"195_CR3","doi-asserted-by":"crossref","unstructured":"Seth P, Rudd RA, Noona RK, Haegerich TM. Quantifying the epidemic of prescription opioid overdose deaths. AJPH April. 2018;108(4).","DOI":"10.2105\/AJPH.2017.304265"},{"key":"195_CR4","unstructured":"https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr67\/nvsr67_09-508.pdf"},{"issue":"6","key":"195_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/15563650701877374","volume":"46","author":"H Schumann","year":"2008","unstructured":"Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JL. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol. 2008;46(6):501\u20136.","journal-title":"Clin Toxicol"},{"key":"195_CR6","doi-asserted-by":"publisher","unstructured":"Bell A, Bennett AS, Jones TS, Doe-Simkins M, Williams LD. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst Abus. 2018. \n                    https:\/\/doi.org\/10.1080\/08897077.2018.1449053\n                    \n                  .","DOI":"10.1080\/08897077.2018.1449053"},{"key":"195_CR7","doi-asserted-by":"crossref","unstructured":"Somerville NJ, O\u2019Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, Ruiz S, Babakhanlou-Chase H, Chan M, Callis BP, Kuramoto-Crawford J, Nields HM, Walley AY. MMWR \/ April 14, 2017 \/ Vol. 66 \/ No. 14.","DOI":"10.15585\/mmwr.mm6614a2"},{"key":"195_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"195_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0196-0644(83)80343-6","volume":"12","author":"KA Handal","year":"1983","unstructured":"Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med. 1983;12(7):438\u201345.","journal-title":"Ann Emerg Med"},{"key":"195_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/978-0-387-73693-8_85","volume":"605","author":"E Sarton","year":"2008","unstructured":"Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid induced respiratory depression with special emphasis on the partial agonist\/antagonist buprenorphine. Ad Exp Med Biol. 2008;605:486\u201391.","journal-title":"Ad Exp Med Biol"},{"issue":"6","key":"195_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.1074","volume":"103","author":"RF Tyndale","year":"2018","unstructured":"Tyndale RF, Sellers EM. Opioids: the painful public health reality. Clinical Pharmacology & Therapeutics. 2018;103(6):924\u201335.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"195_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1749-6632.1976.tb27936.x","volume":"281","author":"EL Way","year":"1976","unstructured":"Way EL, Loh HH. Responsivity To Naloxone During Morphine Dependence. Annals NY Academy of Sciences. 1976;281:252\u201361.","journal-title":"Annals NY Academy of Sciences"},{"key":"195_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/ALN.0b013e3181c38c25","volume":"112","author":"A Dahan","year":"2010","unstructured":"Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226\u201338.","journal-title":"Anesthesiology"},{"issue":"2","key":"195_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/08958378.2017.1282065","volume":"29","author":"B Wong","year":"2017","unstructured":"Wong B, Perkins MW, Tressler J, Rodriguez A, Devorak J, Sciuto AM. Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone. Inhal Toxicol. 2017;29(2):65\u201374.","journal-title":"Inhal Toxicol"},{"issue":"Suppl 2","key":"195_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2885.2012.01409.x","volume":"35","author":"KJ Freise","year":"2012","unstructured":"Freise KJ, Newbound GC, Tudan C, Clark TP. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory beagles. J Vet Pharmacol Ther. 2012;35(Suppl 2):45\u201351.","journal-title":"J Vet Pharmacol Ther"},{"issue":"10","key":"195_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/bja\/53.10.1033","volume":"53","author":"JH Brown","year":"1981","unstructured":"Brown JH, Pleuvry BJ. Antagonism of the respiratory effects of Alfentanil and Fentanil by naloxone in the conscious rabbit. Br J Anaesth. 1981;53(10):1033\u20137.","journal-title":"Br J Anaesth"},{"issue":"2","key":"195_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/bja\/49.2.151","volume":"49","author":"GB Drummond","year":"1977","unstructured":"Drummond GB, Davie IT, Scott DB. Naloxone: dose-dependent antagonism of respiratory depression by fentanyl in anaesthetized patients. BJA: British Journal of Anaesthesia. 1977;49(2):151\u20134.","journal-title":"BJA: British Journal of Anaesthesia"},{"issue":"7","key":"195_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14740338.2015.1037274","volume":"14","author":"HK Kim","year":"2015","unstructured":"Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14(7):1137\u201346. \n                    https:\/\/doi.org\/10.1517\/14740338.2015.1037274\n                    \n                  .","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"195_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1060028015625659","volume":"50","author":"M MacKenzie","year":"2016","unstructured":"MacKenzie M, Zed PJ, Ensom MHH. Opioid pharmacokinetics-pharmacodynamics: clinical implications in acute pain Management in Trauma. Annals of pharmacology. 2016;50(3):209\u201318.","journal-title":"Annals of pharmacology"},{"key":"195_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.forsciint.2018.05.042","volume":"289","author":"K Kuczynska","year":"2018","unstructured":"Kuczynska K, Grzonkowski P, Kacprzak L, Zawilska JB. Abuse of fentanyl: an emerging problem to face. Forensic Sci Int. 2018;289:207\u201314.","journal-title":"Forensic Sci Int"},{"issue":"December","key":"195_CR21","first-page":"1215","volume":"12","author":"TH Stanley","year":"2014","unstructured":"Stanley TH. The fentanyl story, the journal of pain, Vol 15. No. 2014;12(December):1215\u201326.","journal-title":"No"},{"key":"195_CR22","unstructured":"Taylor DR. The pharmacology of fentanyl and its impact on the management of pain, Medscape. Neurology. 2005;7(2) \n                    https:\/\/www.medscape.org\/viewarticle\/518441\n                    \n                  ."},{"key":"195_CR23","doi-asserted-by":"publisher","unstructured":"Burns SM, Cunningham CW, Merce, SL. DARK Classics in Chemical Neuroscience: Fentanyl, ACS Chem Neurosci. 2018;9(10):2428\u20132437. \n                    https:\/\/doi.org\/10.1021\/acschemneuro.8b00174\n                    \n                  . Epub 2018 Jun 12","DOI":"10.1021\/acschemneuro.8b00174"},{"key":"195_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/acem.13034","volume":"24","author":"ME Sutter","year":"2017","unstructured":"Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, Adams AJ, Owen KP, Ford JB, Black HB, Albertson TE. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24:106\u201313.","journal-title":"Acad Emerg Med"},{"issue":"4","key":"195_CR25","first-page":"107","volume":"66","author":"AJ Tomassoni","year":"2017","unstructured":"Tomassoni AJ, Hawk KF, Jubanyik K, Nogee DP, Durant T, Lynch KL, Patel R, Dinh D, Ulrich A, D\u2019Onofrio G. Multiple fentanyl overdoses \u2014 New Haven, Connecticut, June 23, 2016. MMWR. 2017;66(4):107\u201311.","journal-title":"MMWR"},{"key":"195_CR26","doi-asserted-by":"crossref","unstructured":"Fogarty MF, Papsun DM, Logan BK. Analysis of Fentanyl and 18 Novel Fentanyl. Analogs and Metabolites by LC\u2013MS-MS, and report of Fatalities Associated with Methoxyacetylfentanyl and Cyclopropylfentanyl. J Anal Toxicol. 2018:1\u201313.","DOI":"10.1093\/jat\/bky035"},{"key":"195_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","volume":"52","author":"J Lotsch","year":"2013","unstructured":"Lotsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52:23\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"195_CR28","unstructured":"Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA. Acute opioid physical dependence in Postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther. 1989;248(1)."},{"key":"195_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/clpt.1989.10","volume":"45","author":"TJ Gal","year":"1989","unstructured":"Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol and Ther. 1989;45:66\u201371.","journal-title":"Clin Pharmacol and Ther"},{"key":"195_CR30","doi-asserted-by":"crossref","unstructured":"Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among emergency medical service providers is increasing. Prehospital Emergency Care. 21(4):411\u20139.","DOI":"10.1080\/10903127.2017.1315203"},{"issue":"6","key":"195_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/10903127.2017.1335818","volume":"21","author":"R Klebacher","year":"2017","unstructured":"Klebacher R, Harris MI, Ariyaprakai N, Tagore A, Robbins V, Dudley LS, Bauter R, Koneru S, Hill RD, Wasserman E, Shanes A, Merlin MA. Incidence of Naloxone Redosing. in the Age of the New Opioid Epidemic. Prehosp Emerg Care. 2017;21(6):682\u20137.","journal-title":"Prehosp Emerg Care"},{"issue":"1","key":"195_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jemermed.2018.04.022","volume":"55","author":"CA Marco","year":"2018","unstructured":"Marco CA, Trautman W, Cook A, Mann D, Rasp J, Perkins O, Ballester M. naloxone use among emergency department patients with opioid overdose. The Journal of Emergency Medicine. 2018;55(1):64\u201370.","journal-title":"The Journal of Emergency Medicine"},{"key":"195_CR33","doi-asserted-by":"crossref","unstructured":"Wong B, Perkins MW, Tressler J, Rodriguez A, Devorak J, Sciuto AM. Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone. Inhal Toxicol. 29(2):65\u201374.","DOI":"10.1080\/08958378.2017.1282065"},{"key":"195_CR34","unstructured":"Narcan Summary Basis of Approval, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/summary_review\/2017\/208411s001SumR.pdf"},{"key":"195_CR35","unstructured":"Evzio product insert. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209862lbl.pdf"},{"key":"195_CR36","unstructured":"FDA Advisory Committee 2016 \n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM533421"},{"key":"195_CR37","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209862Orig1s000SumR.pdf"},{"issue":"1","key":"195_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","volume":"9","author":"RR Lynn","year":"2018","unstructured":"Lynn RR, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63\u201388.","journal-title":"Ther Adv Drug Saf"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13011-019-0195-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-019-0195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T10:38:07Z","timestamp":1582022287000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-019-0195-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1186\/s13011-019-0195-4","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Adamis Pharmaceuticals which supported this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"6"}}